Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension

Orphanet Journal of Rare Diseases

Diana Valverde¹  Adolfo Baloira²  Guillermo Pousada¹ 

[1] Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain;Complexo Hospitalario Universitario de Pontevedra, Servicio de Neumología, Pontevedra, Spain

关键词: Correlation genotype/phenotype;    Polymorphism;    AGTR1;    TRPC6;    Pulmonary Arterial Hypertension;   

Others  :  1138528
DOI  :  10.1186/s13023-014-0216-3

 received in 2014-10-08, accepted in 2014-12-17,  发布年份 2015

【 摘 要 】

Background

Pulmonary arterial hypertension (PAH) is a rare and progressive vascular disorder characterized by increased pulmonary vascular resistance and right heart failure. The aim of this study was to analyze 5′UTR region in canonical transient receptor potential isoform 6 (TRPC6) and 3′UTR region in Angiotensin II type I receptor (AGTR1) genes in patients with idiopathic and associated PAH. Correlation among mutations and clinical and functional parameters was further analyzed.

Methods

Analysis of TRPC6 and AGTR1 genes was performed by polymerase chain reaction (PCR) and direct sequencing. We used a non-parametric test to determine if significant differences were found between the groups studied and chi-square test to compare clinical and hemodynamic variables among genotypes.

Results

Fifty five patients and fifty two controls were included in this study. We found statistically significant differences for c.1-361A > T (p = 0.0077), c.1-254C > G (p < 0.0001) and c.1-218C > T (p = 0.0021) in TRPC6 gene and c.1166A > C (p < 0.001) in AGTR1 gene, between patients and controls. Idiopathic PAH patients (IPAH) and controls presented significant differences for all 3 TRPC6 polymorphisms (p = 0.020), (p = 0.002) and (p = 0.008) respectively, and also showed differences for AGTR1 gene (p < 0.001). In associated PAH (APAH) patients we found statistical differences for c.1-254C > G (p < 0.001) and c.1-218C > T (p = 0.001) in TRPC6 gene and c.1166A > C (p = 0.001) in AGTR1 gene. Several clinical and hemodynamic parameters showed significant differences between carriers and non-carriers of these single nucleotide polymorphisms (SNPs). Nineteen patients were carriers of all 3 SNPs in TRPC6 gene and presented a more severe phenotype with differences in mean pulmonary arterial pressure (p = 0.016), systolic pulmonary arterial pressure (p = 0.040), cardiac index (p < 0.001) and 6 minute walking test (p = 0.049). 16 of these patients harbored the SNP in AGTR1 gene. These patients showed differences in age at diagnosis (p = 0.049), mean pulmonary arterial pressure (p = 0.033), cardiac index (p = 0.002) and 6 minute walking test (p = 0.039).

Conclusions

PAH is a rare disease with pulmonary vascular remodeling caused in part by a heterogeneous constellation of genetic arrangements. This study seems to suggest that c.1-361A > T, c.1-254C > G and c.1-218C > T polymorphisms in TRPC6 gene and c.1166A > C polymorphism in AGTR1 could have a role in the development of this disease.

【 授权许可】

   
2015 Pousada et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al.: Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013, 62:25S.
• [2]Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S: An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007, 30:104-9.
• [3]Sanchez O, Marié E, Lerolle U, Wermert D, Israël-Biel D, Meyer G: Pulmonary arterial hypertension in women. Rev Mal Respir 2010, 27:e79-87.
• [4]D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115:343-9.
• [5]Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62:25s.
• [6]Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, et al.: Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2013, 62:25S.
• [7]Baloira A, Vilariño C, Leiro V, Valverde D: Mutations in the gene encoding bone morphogenetic protein receptor 2 in patients with idiopathic pulmonary arterial hypertension. Arch Bronconeumol 2008, 44(1):29-34.
• [8]Machado RD, Eickelberg O, Elliott G, Geraci MW, Hanaoka M, Loyd JE, et al.: Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54(Suppl 1):S32-42.
• [9]Yang X, Long L, Reynolds PN, Morrell NW: Expression of mutant BMPR-II in pulmonary endothelial cells promotes apoptosis and a release of factors that stimulate proliferation of pulmonary arterial smooth muscle cells. Pulm Circ 2011, 1(1):103-11.
• [10]Pffar N, Szamalek-Hoegel J, Fischer C, Hinderhofer K, Nagel C, Eklken N, et al.: Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. Respir Res 2011, 12:99-109. BioMed Central Full Text
• [11]Ulrich S, Szamalek-Hoegel J, Hersberger M, Fischler M, García JS, Huber LC, et al.: Sequence variants in BMPR2 and genes involved in the serotonin and nitric oxide pathways in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: relation to clinical parameters and comparison with left heart disease. Respiration 2010, 79:279-87.
• [12]Pousada G, Baloira A, Vilariño C, Cifrián JM, Valverde D: Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS ONE 2014, 9(6):e100261.
• [13]Pfarr N, Fischer C, Ehlken N, Becker-Grünig T, López-González V, Gorenflo M, et al.: Hemodynamic and genetic analysis in children with idiopathic, heritable, and congenital heart disease associated pulmonary arterial hypertension. Respir Res 2013, 14:3-12. BioMed Central Full Text
• [14]Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Plastoshyn O, et al.: Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. PNAS 2004, 101(38):13861-6.
• [15]Xia Y, Yang XR, Fu Z, Paudel O, Abramowitz J, Birnbaumer L, et al.: Classical transient receptor potential 1 and 6 contribute to hypoxic pulmonary hypertension through differential regulation of pulmonary vascular functions. Hypertension 2014, 63:173-80.
• [16]Alzoubi A, Almalouf P, Toba M, O’Neill K, Qian X, Francis M, et al.: TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension. Am J Pathol 2013, 183:1779-88.
• [17]Weissmann N, Dietrich A, Fuchs B, Kalwa H, Ay M, Dumitrascu R, et al.: Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A 2006, 103:19093-8.
• [18]Zhang Y, Lu W, Yang K, Xu L, Lai N, Tian L, et al.: Bone morphogenetic protein 2 decreases TRPC expression, store-operated Ca(2+) entry, and basal [Ca(2+)]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2013, 304:C833-43.
• [19]Yu Y, Keller SH, Remillard CV, Safrina O, Nicholson A, Zhang SL, et al.: A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 2009, 119:2313-22.
• [20]Palatini P, Ceolotto G, Dorigatti F, Mos L, Santonastaso M, Bratti P, et al.: Angiotensin II type 1 receptor gene polymorphism predicts development of hypertension and metabolic syndrome. Am J Hypertens 2009, 22:208-14.
• [21]Nie SJ, Wen-ru T, Bi-feng C, Jin L, Wen Z, Sheng-jun L, et al.: Haplotype-based case–control study of the human AGTR1 gene and essential hypertension in Han Chinese subjects. Clin Biochem 2010, 43(3):253-8.
• [22]Chassagne C, Eddahibi S, Adamy C, Rideau D, Marotte F, Dubois-Randé J, et al.: Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol 2000, 22:323-32.
• [23]Li Y, Li X, Jia N, Guo S, Chu S, Niu W: Meta-analysis of the association between angiotensin II receptor, type 1 gene A1166C polymorphism and coronary artery disease in Chinese populations. J Renin Angiotensin Aldosterone Syst 2013, 14(1):82-90.
• [24]Gardier S, Vincent M, Lantelme P, Rial MO, Bricca G, Milon H: A1166C polymorphism of angiotensin II type 1 receptor, blood pressure and arterial stiffness in hypertension. J Hypertens 2004, 22:2135-42.
• [25]Chung WK, Deng L, Carroll JS, Mallory N, Diamond B, Rosenzweig EB, et al.: Polymorphism in the angiotensin II type 1 receptor (AGTR1) is associated with age at diagnosis in pulmonary arterial hypertension. J Heart Lung Transplant 2009, 28:373-9.
• [26]Galié N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009, 30(20):2493-537.
• [27]Jíra M, Závodná E, Honzíková N, Nováková Z, Vasků A, Izakovicová Hollá L, et al.: Association of A1166C polymorphism in AT(1) receptor gene with baroreflex sensitivity. Physiol Res 2010, 59(4):517-28.
• [28]Inoue R, Jensen LJ, SHI J, Morita H, Nishida M, Honda A, et al.: Transient receptor potential channels in cardiovascular function and disease. Circ Res 2006, 99:119-31.
• [29]Freichel M, Vennekens R, Olausson J, Stolz S, Philipp SE, WeiBgerber P, et al.: Functional role of TRPC proteins in native systems: implications from knockout and knock-down studies. J Physiol 2005, 567.1:59-66.
• [30]Lu W, Ran P, Zhang D, Lai N, Zhong N, Wang J: Bone morphogenetic protein 4 enhances canonical transient receptor potential expression, store-operated Ca2+ entry, and basal [Ca2]i in rat distal pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2010, 299:C1370-8.
• [31]Kunichika N, Landsberg JW, Yu Y, Kunichika H, Thistlethwaite PA, Rubin LJ, et al.: Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes. Am J Respir Crit Care Med 2004, 170:1101-7.
• [32]Ogawa A, Firth AL, Yao W, Rubin LJ, Yuan JX-J: Prednisolone inhibits PDGF-induced nuclear translocation of NF-κB in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2008, 295:L648-57.
• [33]Boney-Montoya J, Ziegler YS, Curtis CD, Montoya JA, Nardulli AM: Long-range transcriptional control of progesterone receptor gene expression. Mol Endocrinol 2010, 24(2):346-58.
• [34]Xu M, Sham P, Ye Z, Lindpaintner K, He L: A 1166C genetic variation of the angiotensin II type I receptor gene and susceptibility to coronary heart disease: collaborative of 53 studies with 20,435 cases and 23,674 controls. Atherosclerosis 2010, 213(1):30-2.
• [35]Sethupathy P, Borel C, Gagnebin M, Grant GR, Deutsch S, Elton TS, et al.: Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 2007, 81(2):405-13.
• [36]Haas U, Sczakiel G, Laufer SD: MicroRNA-mediated regulation of gene expression is affected by disease-associated SNPs within the 3′-UTR via altered RNA structure. RNA Biol 2012, 9(6):924-37.
• [37]Song S, Yamamura A, Yamamura H, Ayon RJ, Smith KA, Tang H, et al.: Flow shear stress enhances intracellular Ca2+ signaling in pulmonary artery smooth muscle cells from patients with pulmonary arterial hypertension. Am J Physiol Cell Physiol 2014, 307(4):C373-83.